Celyad Oncology SA (CYAD.BR)
EUR 0.5
(4.35%)
EUR 0.5
(4.35%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 902 Thousand EUR | 664.41% |
| 2022 | 118 Thousand EUR | -93.18% |
| 2021 | 1.73 Million EUR | -31.49% |
| 2020 | 2.52 Million EUR | -15.95% |
| 2019 | 3 Million EUR | 240.98% |
| 2018 | 881 Thousand EUR | 9.03% |
| 2017 | 808 Thousand EUR | -11.89% |
| 2016 | 917 Thousand EUR | 114.75% |
| 2015 | 427 Thousand EUR | 53.05% |
| 2014 | 279 Thousand EUR | 928.76% |
| 2013 | 27.12 Thousand EUR | -97.06% |
| 2012 | 921.38 Thousand EUR | 692.54% |
| 2011 | 116.25 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - EUR | 0.0% |
| 2023 FY | 16.63 Million EUR | 13994.07% |
| 2023 Q4 | 902 Thousand EUR | 0.0% |
| 2023 Q2 | 351 Thousand EUR | 0.0% |
| 2022 Q1 | 1.55 Million EUR | -10.12% |
| 2022 Q4 | 16.63 Million EUR | 0.0% |
| 2022 FY | 118 Thousand EUR | -93.18% |
| 2022 Q2 | 1.38 Million EUR | -11.19% |
| 2021 Q4 | 1.73 Million EUR | -9.61% |
| 2021 Q2 | 2.1 Million EUR | -10.12% |
| 2021 Q1 | 2.34 Million EUR | -7.29% |
| 2021 FY | 1.73 Million EUR | -31.49% |
| 2021 Q3 | 1.91 Million EUR | -9.03% |
| 2020 Q4 | 2.52 Million EUR | 0.0% |
| 2020 Q2 | 2.5 Million EUR | 0.0% |
| 2020 FY | 2.52 Million EUR | -15.95% |
| 2019 Q4 | 3 Million EUR | 0.0% |
| 2019 Q2 | 3.49 Million EUR | 0.0% |
| 2019 FY | 3 Million EUR | 240.98% |
| 2018 Q4 | 881 Thousand EUR | 0.0% |
| 2018 FY | 881 Thousand EUR | 9.03% |
| 2018 Q2 | 717 Thousand EUR | 0.0% |
| 2017 FY | 808 Thousand EUR | -11.89% |
| 2017 Q2 | 645 Thousand EUR | 0.0% |
| 2017 Q4 | 808 Thousand EUR | 0.0% |
| 2016 FY | 917 Thousand EUR | 114.75% |
| 2016 Q4 | 917 Thousand EUR | 0.0% |
| 2016 Q2 | 1.2 Million EUR | 0.0% |
| 2015 FY | 427 Thousand EUR | 53.05% |
| 2015 Q2 | 339 Thousand EUR | 0.0% |
| 2015 Q4 | 427 Thousand EUR | 0.0% |
| 2014 FY | 279 Thousand EUR | 928.76% |
| 2014 Q2 | 250.59 Thousand EUR | 0.0% |
| 2014 Q4 | 279 Thousand EUR | 0.0% |
| 2013 Q4 | 27.12 Thousand EUR | 0.0% |
| 2013 Q2 | 64.89 Thousand EUR | 0.0% |
| 2013 FY | 27.12 Thousand EUR | -97.06% |
| 2012 Q4 | 921.38 Thousand EUR | 0.0% |
| 2012 FY | 921.38 Thousand EUR | 692.54% |
| 2011 FY | 116.25 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Nicox S.A. | 25.15 Million EUR | 96.414% |
| European Medical Solutions | 12.71 Million EUR | 92.907% |
| FERMENTALG | 14.33 Million EUR | 93.709% |
| argenx SE | 15.35 Million EUR | 94.125% |
| BioSenic S.A. | 15.57 Million EUR | 94.208% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -162.209% |
| Onward Medical N.V. | 16.3 Million EUR | 94.468% |
| Oxurion NV | 117 Thousand EUR | -670.94% |
| PHAXIAM Therapeutics S.A. | 7.03 Million EUR | 87.169% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.969% |